Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Duopharma Biotech Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Duopharma Biotech Berhad şirketinin toplam hissedar öz sermayesi MYR694.0M ve toplam borcu MYR523.9M olup, bu da borç-öz sermaye oranını 75.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla MYR1.3B ve MYR649.8M dir. Duopharma Biotech Berhad 'in FAVÖK'ü MYR80.5M faiz karşılama oranı 4.1 dur. Şirketin MYR221.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

75.5%

Borç/özkaynak oranı

RM 523.94m

Borç

Faiz karşılama oranı	4.1x
Nakit	RM 221.16m
Eşitlik	RM 693.95m
Toplam yükümlülükler	RM 649.76m
Toplam varlıklar	RM 1.34b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DPHARMA 'nin kısa vadeli varlıkları ( MYR697.2M ) kısa vadeli yükümlülüklerini ( MYR160.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: DPHARMA şirketinin kısa vadeli varlıkları ( MYR697.2M ) uzun vadeli yükümlülüklerini ( MYR489.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DPHARMA 'nin net borç/öz sermaye oranı ( 43.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: DPHARMA şirketinin borç/öz sermaye oranı son 5 yılda 51.8% seviyesinden 75.5% seviyesine yükseldi.

Borç Kapsamı: DPHARMA 'nin borcu işletme nakit akışı ( 10% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: DPHARMA 'in borcuna ilişkin faiz ödemeleri EBIT ( 4.1 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Duopharma Biotech Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Recent updates

Second quarter 2024 earnings released: EPS: RM0.017 (vs RM0.013 in 2Q 2023)

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released

New 90-day high - RM3.29

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço